05/28/2026
This study presents a two-pronged gene therapy approach that simultaneously boosts peak Na⁺ current and Ca²⁺ transient amplitude in cardiomyocytes to combat heart failure. It works by expressing prokaryotic sodium channels (BacNav), which modulate Na⁺/Ca²⁺ exchanger activity and increase sarcoplasmic reticulum calcium stores. In a mouse pressure-overload model of chronic heart failure, AAV9-delivered BacNav therapy rescued contractile deficit, prevented arrhythmias, and improved transcriptomic dysregulation. Our Cal-520 calcium indicator, was used to measure calcium transients in cardiomyocytes—loaded at 10 µM and imaged to track real-time Ca²⁺ dynamics during pacing experiments.
Congrats to Tianwu Yu et al on the publication. Your findings on rescuing cardiac function and preventing arrhythmias in chronic heart failure represent a truly exciting step forward for the field. We are honored that Cal-520 played a role in your research, and it is incredibly rewarding to see our products contribute to work of this caliber. We wish you continued success and look forward to supporting your future discoveries.
Read more
👉 https://www.science.org/doi/full/10.1126/sciadv.ady4551
Learn more about Cal-520 AM
👉 https://www.aatbio.com/products/cal-520-am
